open access

Vol 12, No 2 (2017)
Case Reports
Published online: 2017-04-20
Get Citation

Atrial fibrillation in obese patient treated with rivaroxaban

Michał Orszulak, Marcin Wita, Katarzyna Mizia-Stec
DOI: 10.5603/FC.2017.0030
·
Folia Cardiologica 2017;12(2):200-203.

open access

Vol 12, No 2 (2017)
Case Reports
Published online: 2017-04-20

Abstract

A 47-year-old, obese man (body mass index 36 kg/m2), with paroxysmal atrial fibrillation (AF), was admitted to hospital because of poorly tolerated recurrence of AF episode (heart rate 130 bpm). Patient was chronically treated with rivaroxaban 20 mg qd. Due to often recurrence of arrhythmia, extremely badly tolerated (European Heart Rhythm Association [EHRA] IV) together with signs of tachycardia-induced cardiomyopathy (left ventricular ejection fraction 40%) restoration of sinus rhythm and radiofrequency ablation (circumferential pulmonary vein isolation) were performed. Before procedures, efficacy of anticoagulation treatment was proved by transesophageal echocardiogram revealing no cloth in left atrial appendage. Non-vitamin K oral antagonist anticoagulants are safe and effective medications, even with standard dosing in obese patients.

Abstract

A 47-year-old, obese man (body mass index 36 kg/m2), with paroxysmal atrial fibrillation (AF), was admitted to hospital because of poorly tolerated recurrence of AF episode (heart rate 130 bpm). Patient was chronically treated with rivaroxaban 20 mg qd. Due to often recurrence of arrhythmia, extremely badly tolerated (European Heart Rhythm Association [EHRA] IV) together with signs of tachycardia-induced cardiomyopathy (left ventricular ejection fraction 40%) restoration of sinus rhythm and radiofrequency ablation (circumferential pulmonary vein isolation) were performed. Before procedures, efficacy of anticoagulation treatment was proved by transesophageal echocardiogram revealing no cloth in left atrial appendage. Non-vitamin K oral antagonist anticoagulants are safe and effective medications, even with standard dosing in obese patients.

Get Citation

Keywords

atrial fibrillation, NOAC, obesity

About this article
Title

Atrial fibrillation in obese patient treated with rivaroxaban

Journal

Folia Cardiologica

Issue

Vol 12, No 2 (2017)

Pages

200-203

Published online

2017-04-20

DOI

10.5603/FC.2017.0030

Bibliographic record

Folia Cardiologica 2017;12(2):200-203.

Keywords

atrial fibrillation
NOAC
obesity

Authors

Michał Orszulak
Marcin Wita
Katarzyna Mizia-Stec

References (7)
  1. Stępińska J, Kremis E, Konopka A, et al. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry. Kardiol Pol. 2016; 74(4): 362–371.
  2. Hohnloser SH, Cappato R, Ezekowitz MD, et al. X-VeRT Steering Committee and Investigators, X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014; 35(47): 3346–3355.
  3. Calkins H, Gerstenfeld EP, Schilling R, et al. RE-CIRCUIT Study Steering Committee. RE-CIRCUIT study-randomized evaluation of Dabigatran etexilate compared to warfarin in pulmonary vein ablation: assessment of an uninterrupted periprocedural anticoagulation strategy. Am J Cardiol. 2015; 115(1): 154–155.
  4. Camm AJ, Lip GYH, De Caterina R, et al. ESC Committee for Practice Guidelines-CPG, Document Reviewers, ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14(10): 1385–1413.
  5. Heidbuchel H, Verhamme P, Alings M, et al. Advisors:, European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15(5): 625–651.
  6. Güler E, Babur Güler G, Demir GG, et al. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? Anatol J Cardiol. 2015; 15(12): 1020–1029.
  7. Delgado-Fernández M. The J-ROCKET AF study: a matter of ethnicity or a matter of weight? Circ J. 2013; 77(10): 2636.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl